This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

Recommendations

This guideline includes recommendations on:

• Intractable nausea and vomiting
• Chronic pain
• Spasticity
• Severe treatment-resistant epilepsy
• Prescribing

 Products covered by the guideline include:

• cannabis-based products for medicinal use as set out by the UK Government in the 2018 Regulations
• the licensed products delta-9-tetrahydrocannibinol combined with cannabidiol (Sativex) and nabilone
• plant-derived cannabinoids such as pure cannabidiol (CBD)
• synthetic compounds which are identical in structure to naturally occurring cannabinoids such as delta-9-tetrahydrocannabinol (THC), for example, dronabinol.